Item 1.01. Entry into a Material Definitive Agreement.
On November 15, 2018, Spero Therapeutics, Inc. (the Company) and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P.,
Biotechnology Value Trading Fund OS, L.P. and MSI BVF SPV LLC (collectively, BVF) entered into an Exchange Agreement (the Exchange Agreement) pursuant to which BVF agreed to exchange (the Exchange) an aggregate of
1,000,000 shares of the Companys common stock, par value $0.001 (Common Stock), owned by BVF for an aggregate of 1,000 shares of the Companys newly designated Series B Convertible Preferred Stock, par value $0.001 per share
(Series B Preferred Stock).
As described below, the Series B Preferred Stock has substantially the same terms as the Companys Series A
Preferred Stock, par value $0.001 per share (Series A Preferred Stock), issued in July 2018 and currently held by BVF. The shares of Series B Preferred Stock to be issued in the Exchange shall be convertible into an aggregate of
1,000,000 shares of Common Stock (subject to adjustment as provided in the Certificate of Designation), subject to a 9.99% beneficial ownership blocker provision described below.
As of the date of the Exchange Agreement, BVF represented to the Company that it beneficially owned 1,726,590 shares of Common Stock, representing
approximately 9.49% of the shares of Common Stock outstanding as of such date. In addition, BVF holds 2,220 shares of Series A Preferred Stock, which are convertible into 2,220,000 shares of Common Stock (subject to adjustment as provided in the
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the Series A Certificate of Designation), subject to a 9.99% beneficial ownership blocker provision set forth in the Series A
Certificate of Designation.
The Exchange is expected to close on or around November 19, 2018.
A copy of the Exchange Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The foregoing is only a brief description of the
material terms of the Exchange Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text of the Exchange Agreement. The representations, warranties and covenants made by the Company in the Exchange
Agreement were made solely for the benefit of the parties to the Exchange Agreement, including, in some cases, for the purpose of allocating risk among the parties thereto, and should not be deemed to be a representation, warranty or covenant to
investors. Moreover, such representations, warranties or covenants were made as of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of the
Companys affairs.